Generic Lyrica CR Availability
See also: Generic Lyrica
Lyrica CR is a brand name of pregabalin, approved by the FDA in the following formulation(s):
LYRICA CR (pregabalin - tablet, extended release;oral)
-
Manufacturer: PF PRISM CV
Approval date: October 11, 2017
Strength(s): 82.5MG [RLD], 165MG [RLD], 330MG [RLD]
Has a generic version of Lyrica CR been approved?
No. There is currently no therapeutically equivalent version of Lyrica CR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lyrica CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Solid pharmaceutical compositions containing pregabalin
Patent 10,022,447
Issued: July 17, 2018
Assignee(s): Warner-Lambert Company LLCA solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
Patent expiration dates:
- November 2, 2026✓
- November 2, 2026✓
- November 2, 2026
-
Patent 10022447*
Patent expiration dates:
- May 2, 2027
- May 2, 2027
-
Gamma amino butyric acid analogs and optical isomers
Patent 6,197,819
Issued: March 6, 2001
Inventor(s): Silverman; Richard B. & Andruszkiewicz; Ryszard
Assignee(s): Northwestern UniversityA compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.
Patent expiration dates:
- December 30, 2018✓✓
- June 30, 2019✓
- December 30, 2018
-
Solid pharmaceutical compositions containing pregabalin
Patent 8,945,620
Issued: February 3, 2015
Assignee(s): Warner-Lambert Company LLCA solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
Patent expiration dates:
- November 2, 2026✓✓
- November 2, 2026✓✓
- May 2, 2027✓
- November 2, 2026
-
Solid pharmaceutical compositions containing pregabalin
Patent 9,144,559
Issued: September 29, 2015
Assignee(s): Warner-Lambert Company LLCA solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
Patent expiration dates:
- November 2, 2026✓
- May 2, 2027✓
- November 2, 2026
-
Isobutylgaba and its derivatives for the treatment of pain
Patent RE41920
Issued: November 9, 2010
Inventor(s): Singh; Lakhbir
Assignee(s): Warner-Lambert Company LLCThe instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
Patent expiration dates:
- December 30, 2018✓
- December 30, 2018✓
- June 30, 2019✓
- December 30, 2018
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 11, 2020 - NEW PRODUCT
- April 11, 2021 - PEDIATRIC EXCLUSIVITY
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Lyrica CR (pregabalin)
- Lyrica CR Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 2 Reviews
- Drug class: gamma-aminobutyric acid analogs
- FDA Alerts (1)
Consumer resources
Other brands: Lyrica
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |